Erbitux – first treatment in 30 years to prolong survival in 1st-line recurrent and/or metastatic head and neck cancer
Source: www.medicalnewstoday.com Author: staff Data presented at the 33rd European Society for Medical Oncology (ESMO) Congress in Stockholm demonstrate that the [...]